Investment
Features
FeesSafety
Academy
More
Pluang+

Valkea Resources to join Gentile Mining Investor Forum in London on Oct 19, boosting exposure amid key drilling season.

Market News
18 Sep 2026
Newsfile Corp
View Source
Bullish
Valkea Resources to join Gentile Mining Investor Forum in London on Oct 19, boosting exposure amid key drilling season.

Valkea Resources announced its participation in the first Gentile Mining Investor Forum in London on October 19, 2026. The event gathers over 20 mining companies and up to 150 investors for networking and one-on-one meetings, providing Valkea with direct access to a global investor base. This participation coincides with Valkea's increased activity as it begins winter drilling campaigns in Finland's Central Lapland Greenstone Belt, aiming to discover new gold and base metal deposits. The forum, backed by notable sponsors and organized by strategic investor Michael Gentile and Amvest Capital, highlights Valkea's strategic efforts to attract investment during a critical exploration phase.

Valkea Resources news is presented with Basic Materials sector data for context. For readers following Basic Materials, here is Pluang's market snapshot as of Sep 18, 2026 19:13 WIB: Out of 34 priced US stocks, 20 rose and 13 fell. Teck Resources rose 1.32% to USD 66.08 with a typical hold time of 4 days. ArcelorMittal SA fell 1.22% to USD 74.26 with 100% buy order activity and a 35-day hold time. Kinross Gold Corporation rose 1.00% to USD 28.76 with 99% buy order activity and a 52-day hold time.

More News

Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals halted new patient enrollment in its psychiatry clinical trials for the drug azetukalner after reports of neuropsychiatric side effects. This pause led to a sharp 27.6% drop in its stock price, marking its worst day since 2017. ...

Market News
Bearish
47 minutes ago
Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma reported an EPS of -$0.24, beating analyst estimates of -$0.29, and revenue of $6.5 million, slightly above expectations. The company secured a strategic partnership with Sobi for its drug lacutamab, receiving a $75 million upfront paym...

Company Fundamentals
Bullish
1 hour ago
Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex, a provider of human capital management solutions, will release its Q1 fiscal 2027 earnings on September 23, 2026. Analysts expect earnings per share (EPS) of $1.32, up from $1.22 last year, and revenue of about $1.63 billion, higher than las...

Company Fundamentals
Bullish
2 hours ago
Barclays cuts Lennar price target to $70 amid weak Q3 earnings and housing market challenges

Barclays cuts Lennar price target to $70 amid weak Q3 earnings and housing market challenges

Barclays lowered its price target for Lennar Corporation to $70 from a higher level, citing a 52% drop in Q3 net earnings to $284 million and an 8.6% revenue decline to $8.05 billion. The homebuilder faces headwinds from rising mortgage rates and wea...

Analyst Insights
Bearish
2 hours ago
Guggenheim raises price target for Restaurant Brands International to $86 amid growth and share buybacks

Guggenheim raises price target for Restaurant Brands International to $86 amid growth and share buybacks

Guggenheim has raised its price target for Restaurant Brands International (QSR) to $86 from $85 and reiterated a Buy rating, reflecting confidence in the company's strategic growth. Restaurant Brands International is enhancing shareholder value thro...

Analyst Insights
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App